243 related articles for article (PubMed ID: 22393939)
1. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
Lesuisse D; Mauger J; Nemecek C; Maignan S; Boiziau J; Harlow G; Hittinger A; Ruf S; Strobel H; Nair A; Ritter K; Malleron JL; Dagallier A; El-Ahmad Y; Guilloteau JP; Guizani H; Bouchard H; Venot C
Bioorg Med Chem Lett; 2011 Apr; 21(8):2224-8. PubMed ID: 21441024
[TBL] [Abstract][Full Text] [Related]
4. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
5. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
6. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
Wood ER; Shewchuk L; Hassel A; Nichols J; Truesdale AT; Smith D; Carter HL; Weaver K; Barrett G; Leesnitzer T; Alvarez E; Bardera AI; Alamillo A; Cantizani J; Martin J; Smith GK; Jensen DE; Xie H; Mook R; Kumar R; Kuntz K
Biochem Pharmacol; 2009 Dec; 78(12):1438-47. PubMed ID: 19665448
[TBL] [Abstract][Full Text] [Related]
7. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Mulvihill MJ; Cooke A; Rosenfeld-Franklin M; Buck E; Foreman K; Landfair D; O'Connor M; Pirritt C; Sun Y; Yao Y; Arnold LD; Gibson NW; Ji QS
Future Med Chem; 2009 Sep; 1(6):1153-71. PubMed ID: 21425998
[TBL] [Abstract][Full Text] [Related]
8. Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.
Sampognaro AJ; Wittman MD; Carboni JM; Chang C; Greer AF; Hurlburt WW; Sack JS; Vyas DM
Bioorg Med Chem Lett; 2010 Sep; 20(17):5027-30. PubMed ID: 20675137
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Wittman MD; Carboni JM; Yang Z; Lee FY; Antman M; Attar R; Balimane P; Chang C; Chen C; Discenza L; Frennesson D; Gottardis MM; Greer A; Hurlburt W; Johnson W; Langley DR; Li A; Li J; Liu P; Mastalerz H; Mathur A; Menard K; Patel K; Sack J; Sang X; Saulnier M; Smith D; Stefanski K; Trainor G; Velaparthi U; Zhang G; Zimmermann K; Vyas DM
J Med Chem; 2009 Dec; 52(23):7360-3. PubMed ID: 19778024
[TBL] [Abstract][Full Text] [Related]
13. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.
Chamberlain SD; Wilson JW; Deanda F; Patnaik S; Redman AM; Yang B; Shewchuk L; Sabbatini P; Leesnitzer MA; Groy A; Atkins C; Gerding R; Hassell AM; Lei H; Mook RA; Moorthy G; Rowand JL; Stevens KL; Kumar R; Shotwell JB
Bioorg Med Chem Lett; 2009 Jan; 19(2):469-73. PubMed ID: 19056263
[TBL] [Abstract][Full Text] [Related]
15. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
[TBL] [Abstract][Full Text] [Related]
16. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [
